Form 4: Verastem Director Brian M. Stuglik Executes Option Exchange Program
SEC Form 4 Filing
Director Brian M. Stuglik participated in Verastem's option exchange program, resulting in the cancellation of existing stock options and the grant of new options.
Summary
- On March 11, 2024, Brian M. Stuglik, a director of Verastem, Inc., participated in the company's option exchange program.
- As part of this program, certain unexercised stock options with an exercise price greater than $15.00 were cancelled.
- In exchange, Stuglik received a grant of 12,572 new stock options.
- These new options will vest in two equal installments over a two-year period from March 11, 2024, contingent upon continued service as a director or service provider.
- Specifically, 4,166 options with an exercise price of $59.04 and 7,699 options with an exercise price of $21.72 were cancelled.
- The cancelled options were originally granted on June 21, 2018, and June 21, 2019, respectively, with vesting schedules as described in the document.
Sentiment
Score: 6
Explanation: The document describes a routine transaction (option exchange). It's neither particularly positive nor negative, but suggests ongoing efforts to align management incentives.
Positives
- The option exchange program may incentivize continued service and alignment of interests between the director and the company.
- The new options vest over a two-year period, potentially encouraging long-term commitment.
Future Outlook
The director's future compensation is tied to the performance of the company's stock through the vesting of the new stock options.
Industry Context
Option exchange programs are a common practice in the biotech industry to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Option exchange programs are frequently used in the biotechnology industry to refresh equity incentives and retain key personnel.
- Companies like Amgen and Gilead have used similar programs to adjust option grants based on current market conditions and employee performance.
- The vesting schedule of the new options (two years) is fairly standard compared to industry norms, which often range from two to four years.
Stakeholder Impact
- The option exchange program could potentially benefit shareholders by aligning the director's interests with the company's long-term success.
- The director benefits from the new option grant, which provides an incentive to increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| October 2, 2017 | Start date of monthly vesting installments for options granted June 21, 2018. |
| September 2, 2018 | End date of monthly vesting installments for options granted June 21, 2018. |
| June 21, 2018 | Date of grant for cancelled stock options with an exercise price of $59.04. |
| June 21, 2019 | Date of grant for cancelled stock options with an exercise price of $21.72. |
| July 21, 2019 | Start date of monthly vesting installments for options granted June 21, 2019. |
| June 21, 2020 | End date of monthly vesting installments for options granted June 21, 2019. |
| March 11, 2024 | Date of the option exchange program and grant of new stock options. |
| March 11, 2024 | Start date of vesting for new stock options. |
| March 13, 2024 | Date of signature on the Form 4 filing. |
| June 11, 2028 | Expiration date of cancelled stock options with an exercise price of $59.04. |
| June 21, 2029 | Expiration date of cancelled stock options with an exercise price of $21.72. |
| March 11, 2034 | Expiration date of new stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.